BIOA — BioAge Labs, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1709941 ·
Last close
$9.04
Market Cap
$401.85M
52W High
$25.95
52W Low
$8.65
ADV30
1,015,833
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,772,000 | — | -25,375,000 | -22,253,000 | 397,654,000 | 241,777,000 | 18,533,000 |
| Dec 2025 | 3,078,000 | — | -28,423,000 | -25,943,000 | 294,889,000 | 188,888,000 | 22,838,000 |
| Sep 2025 | 2,054,000 | — | -23,140,000 | -20,171,000 | 305,090,000 | 215,573,000 | 27,626,000 |
| Jun 2025 | 2,412,000 | — | -24,771,000 | -21,563,000 | 322,148,000 | 220,330,000 | 27,367,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-81,627,000
Investing CF
$-95,216,000
Financing CF
$11,469,000
CapEx
$-719,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.22
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-333,416,000
Inventory
—
Receivables
$769,000
ST Investments
$92,210,000
EBIT TTM
$-79,908,000
Pretax Income TTM
$-80,605,000
Interest Exp TTM
$697,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,316,000
EBITDA
$-101,470,000
Free Cash Flow
$-58,337,752
Enterprise Value
$22,692,716
Total Cash
$383,193,984
Total Debt
$4,034,000
Shares Out
44,452,734
Trailing EPS
$-2.40
Book Value
$8.54
ROE
-26.0%
ROA
-17.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 8,995,000 | -92,780,000 | -80,605,000 | 294,889,000 | 22,838,000 | — | -81,627,000 |
| Dec 2024 | 0 | -78,194,000 | -71,109,000 | 358,234,000 | 35,107,000 | — | -51,522,000 |
| Dec 2023 | 0 | -48,400,000 | -63,854,000 | 25,924,000 | 199,320,000 | — | -37,362,000 |
| Dec 2022 | 0 | -39,969,000 | -39,722,000 | 28,429,000 | 140,988,000 | — | -36,181,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BNTC | Benitec Biopharma Inc. | $402.29M | $11.71 | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $403.63M | $7.93 | — |
| EVMN | Evommune, Inc. | $405.21M | $11.25 | — |
| LRMR | Larimar Therapeutics, Inc. | $396.83M | $3.82 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $409.30M | $0.38 | — |
News headlines (Yahoo Finance, 1h cache)
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
2026-07-31 21:56 · Yahoo
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
2026-07-14 15:41 · Yahoo
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
2026-07-14 13:30 · Yahoo
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?
2026-06-30 13:09 · Yahoo
BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor
2026-06-25 00:22 · Yahoo
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
2026-06-16 12:00 · Yahoo
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
2026-06-06 12:04 · Yahoo
BioAge Labs to Present at Upcoming Investor Conferences
2026-05-22 13:00 · Yahoo
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?
2026-05-20 20:43 · Yahoo
This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday
2026-05-13 17:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.